Azacitidine with checkpoint inhibitors for AML and MDS

There has been growing evidence that the combination of hypomethylating agents like azacitidine with immune checkpoint inhibitors could be a highly potent treatment option in acute myeloid leukemia (A... Author: VJHemOnc Added: 07/31/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts